HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.5%

Neg 0% Neu 88.5% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.